淋巴细胞功能相关抗原3在低分级胶质瘤中的表达及临床意义

摘要

Objective:To explore the relationship of lymphocyte function-associated antigen 3 (LFA-3, CD58) expression in glioma with clinical features and its role in clinical prognosis. Methods:Clinical data and mRNA microarray data of 514 patients with glioma were obtained from The Cancer Genome Atlas and were used to study the expression of LFA-3 (CD58). Cox regression was used to analyze the relationship between CD58 expression and survival of patients with glioma. Multivariate analysis of variance was used to further analyze the relationship of CD58 with age, sex, and pathological grade of glioma. Results:The results of the stratified χ2 test of CD58 expression and tumor grading were shown, considering tumor type, gender and age of diagnosis (all P<0.05). CD58 expression was sig-nificantly correlated with overall survival (OS) and disease-free survival (DFS) of patients with glioma. Patients with high CD58 expres-sion presented short OS and DFS (P<0.0001). Conclusion:CD58 possibly promotes tumorigenesis in gliomas and thus can serve as a potential tumor diagnostic marker and individual therapeutic target.%目的:探索CD58又称淋巴细胞功能相关抗原3(lymphocyte function-associated antigen 3,LFA-3)在低分级胶质瘤中的表达及其与临床特征之间的关系,并探讨其在临床预后判断中的作用.方法:收集癌症基因图谱(The Cancer Genome Atlas,TCGA)数据库中514例低分级胶质瘤患者的临床资料和mRNA芯片数据,对LFA-3(CD58)进行表达分析.Cox多因素回归分析CD58的表达水平与脑胶质瘤患者无病生存期(disease free survival,DFS)以及总生存期(overall survival,OS)之间的关系.进一步通过χ2检验分析,研究CD58与患者年龄、性别以及脑胶质瘤病理级别等之间的关系.结果:CD58表达水平随脑胶质瘤病理级别升高而升高,CD58表达量与肿瘤分级的分层χ2检验结果表明,在考虑肿瘤类型、性别和诊断年龄这3个因素后,CD58表达量与肿瘤分级仍然相关,均P<0.05.CD58的表达水平显著影响胶质瘤患者的DFS和OS,CD58表达越高患者DFS和OS越短(P<0.0001).结论:CD58在脑胶质瘤中可能起到促进肿瘤的作用,可以作为潜在的肿瘤诊断标志物以及个体化治疗的靶点.